Author

W. Chatila

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Santella· 1 shared A.-K. Hadjantonakis· 1 shared C. B. Thompson· 1 shared D. G. Macalinao· 1 shared D. Pe'er· 1 shared E. Brogi· 1 shared E. Seffar· 1 shared F. Sanchez-Vega· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Santella

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Distinct tumor architectures for metastatic colonization of the brain

S. Gan, D. G. Macalinao, S. H. Shahoei, L. Tian, X. Jin, H. Basnet, J. T. Muller, P. Atri, E. Seffar, W. Chatila, A.-K. Hadjantonakis, N. Schultz, E. Brogi, T. A. Bale, D. Pe'er, J. Massague

This study compares the brain metastasis colonization strategies of triple-negative breast cancer and HER2+ breast cancer, revealing distinct tumor architectures and stromal interactions.

bioRxiv · Jan 27, 2023 · PreprintCancer Biology

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burden

J. M. Schvartzman, G. C. Forsyth, H. Walch, W. Chatila, A. Santella, K. Menghrajani, F. Sanchez-Vega, R. Koche, C. B. Thompson

This study shows that IDH mutations cause replication stress through heterochromatin, affecting DNA repair and PARP inhibitor response without increasing mutation burden.

bioRxiv · Aug 4, 2022 · PreprintCancer Biology